bearish
Pacific Edge (PEB): LCD Update – Signs of Life
The implementation of LCD, L35396 “Genetic Testing for Oncology” that would have resulted in Pacific Edge’s (PEB) CMS reimbursement ceasing on 17 July 2023 has been delayed; In the interim, PEB will continue to be reimbursed for its CMS tests (~77% of FY23 operating revenue) which is a clear near-term positive against prior expectations of a significant revenue reduction and business disruption
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Forsyth Barr
New Zealand Professional Investment Services Firm
Price Chart(Sign Up to Access)
- Loading...
x